Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LGMN | Q99538 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25034811 | 0.93 | MAPT (0.49) | MAPTKDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25935140 | 0.90 | MAPT (0.51) | MAPTKDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25819440 | 0.87 | MAPT (0.46) | MAPTKDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25935365 | 0.86 | PDK2 (0.48) | MAPTKDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25935029 | 0.85 | FFAR4 (0.46) | MAPTKDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25935354 | 0.84 | HPGD (0.50) | MAPTKDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25819577 | 0.84 | HTR1A (0.41) | — | |
| SCHEMBL25819578 | 0.84 | HTR1A (0.45) | — | |
| SCHEMBL25029392 | 0.83 | MAPT (0.49) | MAPTKDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30479001 | 0.80 | MAPT (0.45) | MAPTKDM4EMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | MAPT 2055/4885KDM4E 1918/4885MEN1 3403/4885 |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | MAPT 1700/4885KDM4E 1387/4885MEN1 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.